Ajay Royyuru leads Healthcare & Life Sciences research at IBM. His team is actively pursuing high-quality science, developing novel technologies and achieving translational insights across this industry, including areas of cancer, cardiac, neurological, mental health, immune system, and infectious diseases. Working with institutions around the world, he is engaged in research that will advance personalized, information-based medicine. His scientific interests and active projects include; genomics, protein science, systems biology, computational neuroscience, health informatics, miniaturizing for medical devices, and nano-biotechnology. His work has been featured in The New York Times, The Washington Post, BBC, Forbes, Scientific American, Nature Medicine, and Nature news articles.
Andre Nel is a Distinguished Professor of Medicine and is Founder and Chief of the Division of Nanomedicine. Also, he is the Director of the University of California’s Center for Environmental Implications of Nanotechnology (UC CEIN), a $48 million National Science Foundation (NSF) and Environmental Protection Agency (EPA) funded multidisciplinary and multi-institutional center for nanosafety implementation in the US. His research interests are: (i) Nanomedicine and Nanobiology, including nanomaterial therapeutic devices and the study of nanomaterial properties that lead to biocompatible and biohazardous interactions in humans and the environment; (ii) The role of air pollutants in asthma, with particular emphasis on the part of ultrafine particle-induced oxidative stress in the generation of airway inflammation and asthma. Dr. Nel serves as Associate Editor of ACS Nano, an internationally recognized journal.
Dr. Chad A. Mirkin is the Director of the International Institute for Nanotechnology and the George B. Rathmann Professor of Chemistry, Professor of Chemical and Biological Engineering, Professor of Biomedical Engineering, Professor of Materials Science and Engineering, and Professor of Medicine at Northwestern University. He is a chemist and a world-renowned nanoscience expert, who has authored over 700 papers; he is an inventor on over 1,000 patents and applications worldwide (over 300 issued). Mirkin has been recognized for his accomplishments with over 120 national and international awards. These include the RUSNANOPRIZE, the Dan David Prize, the Wilhelm Exner Medal, the Sackler Prize in Convergence Research, the $500,000 Lemelson-MIT Prize, and the ACS Award for Creative Invention. He was a Member of the President's Council of Advisors on Science and Technology (PCAST, Obama Administration), and one of fewer than 20 scientists, engineers, and medical doctors to be elected to all three US National Academies (National Academy of Medicine, the National Academy of Sciences, and the National Academy of Engineering). He is also a Fellow of the American Academy of Arts and Sciences, the Materials Research Society, the American Chemical Society, the National Academy of Inventors, and the American Institute for Medical and Biological Engineering. He is the Founding Editor of the journal Small, and he has founded multiple companies, including AuraSense, Exicure, TERA-print, and CDJ Technologies. Mirkin holds a B.S. degree from Dickinson College and a Ph.D. degree from Penn State. He was an NSF Postdoc at MIT prior to becoming a Professor at Northwestern in 1991.
Dr. Chih-Ming Ho received his Ph.D. from Johns Hopkins University. He held the Ben Rich-Lockheed Martin Professor Chair until he retired in 2016 and currently is a UCLA Distinguished Research Professor. He served as UCLA Associate Vice Chancellor for Research from 2001 to 2005. His research interests include phenotypic personalized medicine (PPM), micro/nano fluidics, molecular sensors and turbulence. He was ranked by ISI as one of the top 250 most cited researchers in all engineering categories (2001-2014). Dr. Ho was inducted as a member of the National Academy of Engineering and an Academician of Academia Sinica. He has received a Doctor of Engineering Honoris Causa from Hong Kong University of Science and Technology and Dr. Ho holds ten honorary professorships, including the Einstein Professor from the Chinese Academy of Sciences. Dr. Ho was elected as Fellow of AAAS, APS, AIMBE, AIAA and 3M-Nano Society
Elsa Sotiriadis is a scientist, former venture capital investor, futurist and science fiction writer (Elsa Solaris). She is interested in fixing the world by hacking the code of life. As a director at a VC firm, she helped invest in, build, and launch 25 pioneering biotech startups to transform industries across food, technology, health, and medicine. During her Ph.D. in Synthetic Biology at Imperial College London, she worked on making DNA nanorobots to stop the growth of cancer cells. Today, as a ‘Bio-Futurist’ she helped an iconic tech company harness digital biology to innovate their flagship product. She has been featured in the BBC’s science fiction show ‘Forest 404’ and took part in a workshop on self-sustaining human life in space at NASA’s Ames Research Centre.
Françoise Baylis is a University Research Professor at Dalhousie University. She is a member of the Order of Canada and the Order of Nova Scotia, as well as a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences. Baylis was one of the organizers of, and a key participant in, the 2015 International Summit on Human Gene Editing. She is a member of the WHO expert advisory committee on Developing global standards for governance and oversight of Human Genome editing. Her most recent book is Altered Inheritance: CRISPR and the Ethics of Human Genome Editing.
George Gokel is a Distinguished Professor of Chemistry and Biology in the Department of Chemistry at the University of Missouri-St. Louis. Professor Gokel’s early work was in the area of phase transfer catalysis, and he co-authored the first monograph in that field in 1978. He invented the compounds known as “lariat ethers.” During the past ten years, Professor Gokel has pioneered the development of synthetic cation channels that function in phospholipid bilayer membranes. His research work has produced more than 300 papers and a dozen patents. He has authored, co-authored, or edited fifteen books.
Hanadi Sleiman is a Professor of Chemistry and Canada Research Chair in DNA Nanoscience at McGill University. She received her Ph.D. from Stanford University and was a CNRS postdoctoral fellow in Prof. Jean-Marie Lehn’s laboratory at the Université Louis Pasteur. Her research group focuses on using molecule DNA as a template to assemble nanostructured materials. Sleiman is Fellow of the Royal Society of Canada (2016), Associate Editor of J. Am. Chem. Soc., and Editorial Advisory Board member of J. Am. Chem. Soc., Chem., J. Org. Chem., and ChemBioChem. She received the McGill Principal’s Prize (2002) and the Leo Yaffe Award (2005) for Excellence in Teaching.
HRH Dr. Maha AlSaud is the Vice President of External Relations and Advancement at Alfaisal University (2014-present), a fully accredited NCAAA institute of higher education in the Kingdom of Saudi Arabia. HRH Dr. Maha spearheaded the enrolment of women in 2011 and serves as a member of the Board of Trustees, and Chairperson of the External Relations Advisory Board. HRH Dr. Maha is one of the founders and former Governor of American College of Physicians (ACP 2015 - 2019) – Saudi Arabia. She holds an MBBS degree from King Saud University (Riyadh, Kingdom of Saudi Arabia), College of Medicine (1986). She completed the Residency program at George Washington University Hospital for internal Medicine (1993). She acquired the American Board of Internal Medicine Certification (1994) and continues to hold it. She was also a Board Member at the Primary Vascular Research Institute. She is also the President of George Washington University Medical Alumni, for Saudi Arabia and Gulf region and she is the Lead Co-Chair of the Taskforce #9 “Migration and Young Societies” at G20 Saudi Arabia 2020.
Ian Campbell is the Interim Executive Chair for Innovate UK. The Executive Chair of Innovate UK is the operational head of the organisation, as it continues its leading role in driving the UK’s technology and innovation strategy. Previously he was Director - Ageing Society, Health & Nutrition and Director - Health and Life Sciences. Dr. Campbell has extensive entrepreneurial and business experience in the healthcare sector. Before Innovate UK, Ian was CEO of Arquer Diagnostics, which focuses on bladder and prostate cancer diagnosis. Before this, he spent 15 years in a variety of executive management roles within the health and life science sector.
Jonathan Sessler is a professor of chemistry at The University of Texas at Austin. He is notable for his pioneering work on expanded porphyrins and their applications to biology and medicine. He is a co-founder of Pharmacyclics, Inc., a company that works with expanded porphyrins, and Anionics, Inc., which develops anion recognition chemistry. Pharmacyclics was sold to AbbVie for $21 billion in 2015.
Kimoon Kim is a university distinguished a professor at Pohang University of Science and Technology (POSTECH) and the director of the Center for Self-assembly and Complexity (CSC), Institute for Basic Science (IBS). He received his Ph.D. from Standford University and studied chemistry at Seoul National University. His research focuses on developing novel functional materials and devices based on supramolecular chemistry. In particular, his group has been working on a wide variety of functional materials based on cucurbiturils, a family of pumpkin-shaped macrocyclic molecules, organic or metal-organic porous materials, and self-assembled nanostructured polymer materials. His work has been recognized by several awards, including Izatt-Christensen Award (2012).
Mark Kendall's innovations have generated about $2 Billion in value in healthcare. He has authored more than 200 refereed publications and being an inventor on more than 130 patents (of which more than 70 have been granted so far). While at the University of Oxford, he contributed as an inventor of the biolistics technology, which was commercialized by PowderJect (sold to Chiron for $1 Billion in 2003) and then with PowderMed (the technology transfer company) purchased by Pfizer for $400 million in 2006. In 2018 he joined The Australian National University – and he is seconded fully as CEO into WearOptimo, which's mission is to rapidly advance the next-generation Microwearable devices for precision medicine with an impact on a global scale. He is a fellow of the Royal Society of Arts, Manufactures and Commerce (FRSA) and the Australian Academy of Technological Sciences and Engineering (FTSE). He serves on the World Economic Forum Global Future Council on Biotechnology. Mark has received numerous awards, such as the 2012 Rolex Laureate for pioneering efforts to expand knowledge and improve human life.
Natasha McEnroe is the Keeper of Medicine at the Science Museum in London. Her previous post was Director of the Florence Nightingale Museum, before this, she was Museum Manager of the Grant Museum of Zoology and Comparative Anatomy, and Curator of the Galton Collection at University College London. She has been Curator of Dr. Johnson’s House in London’s Fleet Street and has also worked for the National Trust and the Victoria & Albert Museum. Natasha was co-editor of The Hospital in the Oatfield – The Art of Nursing in the First World War (2014); The Tyranny of Treatment: Samuel Johnson, His Friends and Georgian Medicine (2003); and editor of Medicine: An Imperfect Science(2019) and co-editor of The Medicine Cabinet(2019). Her research interests focus on 18th and 19th-century medical humanities. Natasha is a Freeman of The Worshipful Company of Barbers.
Nicholas Peppas works on a multidisciplinary approach of blending modern molecular and cellular biology with engineering principles to design the next-generation of medical systems and devices for patient treatment. He is the Cockrell Family Regents Chair in the Departments of Biomedical Engineering, Chemical Engineering, and Pediatrics, at the University of Texas at Austin. His work focuses on nanomedicine, biomaterials, drug delivery, bionanotechnology and polymer physics. He has 1,600 publications with 128,000 citations and H=166. Peppas holds a Dipl. Eng. from the NTU of Athens (1971), an Sc.D. from MIT (1973), and honorary doctorates from the Universities of Ghent, Parma, Athens, Patras, Ljubljana, Thessaloniki, Santiago de Compostela, and the National Technical University of Athens. Also, he is an Honorary Professor at Sichuan University, Beihang University, PLA Hospital and Medical School, and Peking Medical Union College in China.
Rene Frydman is part of the Faculty of Medicine at University Paris XI and is the Head of the Department of Gynecology and Obstetrics of Antoine Beclere Hospital. Formerly, Professor Frydman held several national positions including Member of the National Committee of Human Rights, Member of the National Committee of Ethics for the Sciences of Life and Health, or Counselor of the Minister of Research. He received the honor of Chevalier of the French Order Of Merit and is an Officer of the French Legion d’Honneur. His particular areas of interest are in biomedical ethics - he was active in the preparation of the law on bioethics - and Gynecology and Obstetrics, including infertility and high-risk pregnancy. His work in infertility led in 1982 to the first baby born as a result of in vitro fertilization in France.
Rifat Atun is a professor of Global Health Systems at Harvard University and the Faculty Chair of the Harvard Ministerial Leadership Program. Professor Atun's research focuses on health system transformation and innovation. Previously, he served as a member of the Executive Management Team of the Global Fund as Director of Strategy, Performance, and Evaluation where he chaired the panel that oversaw annual investments of ~US$3-4 billion. He was also a Professor of International Health Management at Imperial College London. Prof. Rifat has published over 350 papers in leading journals and has advised more than 30 governments on health policy and health system reform and has worked with the World Bank, WHO and leading organizations such as Medtronic, Novartis, Roche, and Merck & Co.